What LDL-C measures
LDL cholesterol (LDL-C) measures the total mass of cholesterol carried inside low-density lipoprotein particles in your bloodstream. It is typically calculated using the Friedewald equation from a standard lipid panel: LDL-C = Total Cholesterol − HDL-C − (Triglycerides ÷ 5).
LDL-C is the most tested cardiovascular biomarker in India, but it has an important limitation: it measures cholesterol mass, not the number of LDL particles. Two people with identical LDL-C values can have dramatically different cardiovascular risk if one has more, smaller particles.
The particle vs concentration problem
Imagine two containers of identical total cholesterol but different configurations:
- Scenario A: 10 large LDL particles, each carrying a lot of cholesterol → LDL-C = 120 mg/dL, 10 particles
- Scenario B: 30 small, dense LDL particles, each carrying less cholesterol → LDL-C = 120 mg/dL, 30 particles
Both scenarios produce the same LDL-C, but Scenario B has 3× more atherogenic particles — each capable of entering the arterial wall. Small, dense LDL particles are more atherogenic because they penetrate the endothelium more easily, are more susceptible to oxidation, and linger in circulation longer.
This is why ApoB — which directly counts particles — is a more accurate cardiovascular risk marker.
India-specific context
South Asians have a well-documented genetic predisposition toward elevated cardiovascular risk — this includes higher rates of insulin resistance, higher prevalence of small dense LDL particles, elevated Lp(a), and higher rates of early cardiovascular events at lower LDL-C levels compared to European populations.
This makes the "below 130 is normal" threshold particularly dangerous for Indian patients — a 28-year-old with LDL-C of 125 mg/dL and high particle count (measurable via ApoB) has significant risk that standard labs will miss.
Reference ranges vs optimal ranges
| LDL-C Level | Risk Category | India Context | Target / Action |
|---|---|---|---|
| <70 mg/dL | Optimal (high risk) | Target for existing CVD, diabetes, Lp(a) elevation | Maintain; may require statin or PCSK9i |
| 70–100 mg/dL | Optimal (low/moderate risk) | Longevity target for most adults | Maintain with diet and lifestyle |
| 100–130 mg/dL | Borderline elevated | Above longevity target; especially concerning in South Asians | Dietary optimisation, berberine, psyllium, check ApoB |
| 130–160 mg/dL | Elevated | Moderate risk; lab "normal" in India but not optimal | Significant lifestyle change; consider pharmacotherapy if risk factors present |
| >160 mg/dL | High | High cardiovascular risk; possible familial hypercholesterolaemia | Physician evaluation; consider statin therapy |
Dietary levers for LDL-C
- Saturated fat reduction — the strongest dietary lever; saturated fat raises LDL-C by upregulating LDL receptor expression; ghee, coconut oil, red meat, full-fat dairy all contribute
- Trans fat elimination — raises LDL-C and lowers HDL-C simultaneously; avoid vanaspati, margarine, and commercially fried foods
- Soluble fibre increase — psyllium husk (5–10g/day with water), oats, legumes, vegetables; binds bile acids and reduces cholesterol reabsorption; lowers LDL-C 5–10%
- Plant sterols/stanols — 2g/day (found in fortified foods or supplements) blocks intestinal cholesterol absorption; reduces LDL-C 10–15%
Supplements with LDL-C evidence
- Berberine — 500mg twice daily; upregulates LDL receptors via PCSK9 inhibition; RCT data shows 20–30% LDL-C reduction; also lowers triglycerides and improves insulin sensitivity
- Omega-3 EPA+DHA — high dose (3–4g/day) modestly reduces LDL-C; primarily reduces triglycerides 20–50%
- Red yeast rice — contains monacolin K, which is chemically identical to lovastatin; reduces LDL-C 15–25%; use only standardised products; has statin-like side effect profile at higher doses
- Niacin (extended release) — lowers LDL-C and Lp(a); fallen out of favour due to side effects but still used at 1–2g/day under physician guidance
When statins are appropriate
Statins remain the most evidence-based pharmaceutical intervention for LDL-C reduction (30–55%) and have direct outcome data showing reduced cardiovascular events and mortality. They are appropriate when: LDL-C exceeds 160 mg/dL despite lifestyle changes, when existing cardiovascular disease is present, when Lp(a) is elevated adding to risk, or when ASCVD risk score exceeds 10%. The decision requires physician involvement.
If you can only add one additional test to your lipid panel, make it ApoB. It directly counts atherogenic particles and provides information that LDL-C cannot — particularly for South Asians with insulin resistance and small dense LDL. Target ApoB below 80 mg/dL (low risk) or below 60 mg/dL (high risk).
How often to test
Annual lipid panel for adults over 25. If LDL-C is elevated and you are making dietary changes or starting supplements: retest at 3 months. If on statin therapy: retest at 6–8 weeks to confirm response, then annually.
Frequently asked questions
What is a good LDL cholesterol level in India?
Below 100 mg/dL for primary prevention. Below 70 mg/dL for high-risk individuals or existing CVD. Lab normal of "below 130 mg/dL" is not the longevity target, especially for South Asians with higher inherent cardiovascular risk.
How can I lower LDL cholesterol naturally?
Reduce saturated fat, eliminate trans fats, add soluble fibre (psyllium, oats), use berberine 500mg twice daily, add plant sterols 2g/day. Weight loss if overweight reduces LDL-C. These interventions can achieve 20–35% reductions in motivated individuals.
Is LDL the same as ApoB?
No. LDL-C measures cholesterol mass; ApoB counts particles — one ApoB per particle. You can have identical LDL-C but different particle counts. ApoB is more accurate, especially for South Asians who often have small dense LDL particles that carry less cholesterol per particle.
What is the longevity target for LDL cholesterol?
Below 100 mg/dL for low risk; below 70 mg/dL with risk factors. Many longevity cardiologists prioritise ApoB below 80 mg/dL (low risk) or 60 mg/dL (high risk) as the more meaningful target.